Key Segmentation
By Molecule Type
-
Small Molecule
-
Large Molecule
By Service Type
-
Manufacturing
-
Formulation Development
-
Analytical and Testing
-
Others
By Dosage Form
-
Vials and Ampoules
-
Prefilled Syringes
-
Cartridges
-
IV Bags
-
Others
By End User
-
Pharmaceutical Companies
-
Biotechnology Companies
-
Others
Regional Coverage:
North America
-
United States
-
Canada
Europe
-
Germany
-
United Kingdom
-
France
-
Italy
-
Spain
-
Russia
-
Poland
-
Rest of Europe
Asia Pacific
-
China
-
India
-
Japan
-
South Korea
-
Australia
-
ASEAN Countries
-
Rest of Asia Pacific
Middle East & Africa
-
UAE
-
Saudi Arabia
-
Qatar
-
South Africa
-
Rest of Middle East & Africa
Latin America
-
Brazil
-
Argentina
-
Mexico
-
Colombia
-
Rest of Latin America
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
-
Detailed Volume Analysis
-
Criss-Cross segment analysis (e.g. Product X Application)
-
Competitive Product Benchmarking
-
Geographic Analysis
-
Additional countries in any of the regions
-
Customized Data Representation
-
Detailed analysis and profiling of additional market players
Frequently Asked Questions
Key players include Vetter, Simtra BioPharma Solutions, Catalent, Thermo Fisher Scientific, Lonza, Samsung Biologics, Fujifilm Biotechnologies, Recipharm, Siegfried, PCI Pharma Services, Grand River Aseptic Manufacturing, Jubilant HollisterStier, Sharp Services, FAMAR, Piramal Pharma Solutions, WuXi Biologics, CordenPharma, ROIS CDMO, Bora Pharmaceuticals and Lotte Biologics.
Key opportunities include onshoring programs, prefilled syringe and cartridge capacity, antibody-drug conjugate and high-potency filling, and fast-growing Asia Pacific demand.
Growing biologics pipelines and the need for resilient injectable supply are the main growth factors, since most sponsors outsource aseptic filling.
By Molecule Type, the Large Molecule segment dominated the market in 2025 with an estimated 65.11% share, supported by the injectable nature of biologics.
North America dominated the market with a share of 40.18% in 2025, driven by a deep biotechnology pipeline and strong demand for contract fill-finish.